![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ISIS PHARMACEUTICALS LICENSES ANTISENSE DRUG TO ICO THERAPEUTICS FOR THE TREATMENT OF EYE DISEASES
ISIS PHARMACEUTICALS LICENSES ANTISENSE DRUG TO ICO THERAPEUTICS FOR THE TREATMENT OF EYE DISEASES
August 25, 2005
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and iCo Therapeutics Inc. announced today that Isis has granted an exclusive worldwide license to iCo for the development and commercialization of ISIS 13650, a second-generation antisense drug. iCo will initially develop ISIS 13650 for the treatment of various eye diseases caused by the formation of new blood vessels (choroidal neovascularization) such as age-related macular degeneration (AMD) and diabetic retinopathy.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-25-2005/0004094023&EDATE=)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct